Georgia GLP-1 Weight Loss Compliance for Med Spas 2026

Georgia has no GLP-1 statute. There is no weight-loss clinic licence, no anti-obesity medicine rule, and nothing in the Georgia Composite Medical Board's rulebook that names semaglutide or tirzepatide. Operators read that absence as permission, which is the mistake. A Georgia GLP-1 program is governed by four ordinary bodies of law that were written long before these drugs existed, and it is judged against them one link at a time.

Those four links are the spine of this guide: prescribe, administer, compound, monitor. A program can be flawless on three and still be indefensible on the fourth, because a Board investigation does not grade on average. It pulls the chart, reads the protocol agreement, asks where the vial came from, and asks who pushed the plunger.

For the national picture — federal prescribing standards, cross-state telehealth, how other states are enforcing — start with our complete GLP-1 med spa compliance guide. This page does not repeat it. Everything below is Georgia: Georgia statutes, Georgia Board rules, and the Georgia-specific traps that the national guidance does not cover.

Three of Georgia's four regulators are worth naming up front, because they are not interchangeable and operators routinely attribute one's powers to another. The Georgia Composite Medical Board (GCMB) licenses physicians and PAs and approves the delegation instruments that let anyone else prescribe. The Georgia Board of Nursing (GBON) licenses the RNs and LPNs who will actually give the injections. The Georgia State Board of Pharmacy permits the pharmacies, and the Georgia Drugs and Narcotics Agency (GDNA) is the inspection and investigation arm that walks through the door.

Can a Georgia Med Spa Legally Run a GLP-1 Program in 2026?

Yes — and the structure is not complicated. It is simply medical, and most of what goes wrong comes from trying to make it retail.

The structure that holds up

A defensible Georgia GLP-1 program has five parts, and each maps to a section below:

1. A Georgia-licensed prescriber with actual authority for this drug category — physician, PA under a GCMB-approved job description, or APRN under a filed nurse protocol agreement.
2. A documented clinical evaluation, performed by that prescriber, before the first prescription is issued.
3. Product dispensed by a pharmacy lawfully permitted to dispense into Georgia, with the permit number in your file.
4. Administration by a licensed professional acting on a valid, patient-specific order — or by the patient, after a documented teaching visit.
5. A follow-up schedule that actually happens, with titration decisions, tolerance, weight response and stop criteria in the chart.

The structure that gets you disciplined

The failure pattern is consistent enough to describe in a sentence: a membership-style program where a patient signs up online, an unnamed clinician approves a batch of intakes, a vial arrives from a supplier nobody vetted, an unlicensed staff member injects it, and nobody sees the patient again until the card declines. Every one of those five steps breaks a different Georgia rule, which is why these cases produce long consent orders rather than single-count ones.

Note what is not on that list: the med spa setting itself, non-physician ownership, or cash-pay pricing. None of those is unlawful in Georgia. The compliance question is never the business model; it is whether the clinical spine exists underneath it.

Prescribe: Who Holds Prescriptive Authority in Georgia

This is the section most Georgia programs get wrong, because Georgia is a delegation state and delegation is a document, not a relationship. Nobody but a physician prescribes on their own licence here.

Physicians

A Georgia-licensed MD or DO in good standing may prescribe any GLP-1 for weight management, including off-label use of a diabetes-labelled product, subject only to the standard of care. Wegovy and Zepbound carry weight-management indications; Ozempic and Mounjaro are diabetes products, and prescribing them for weight loss is off-label. Off-label prescribing is lawful in Georgia, but the chart has to show the reasoning — why this product, why not the labelled one, and that the patient was told.

Physician assistants and the board-approved job description

A PA's prescriptive authority in Georgia comes from a job description approved by the GCMB, not from the PA licence. Under O.C.G.A. §43-34-103, a physician may delegate to a PA, through that job description, the authority to issue prescription drug orders for dangerous drugs and for Schedule III, IV and V controlled substances. Schedule II is prohibited apart from a narrow emergency carve-out for hydrocodone and oxycodone under §43-34-103(e.1)(1)(B). GLP-1s are neither — they are dangerous drugs, covered squarely by the ordinary delegation.

The operative requirement is that the delegation must actually appear in the approved job description. A 2026 rule change eased the paperwork: where a primary supervising physician already has a board-approved job description on file and applies for a new PA in the same practice, the job description is deemed approved on submission, subject to the Board's power to terminate that approval on review. That is an administrative convenience, not a relaxation of what the document must say.

APRNs and the nurse protocol agreement

Georgia APRNs do not have independent prescriptive authority, and no amount of experience changes that. An APRN may issue a prescription drug order only under a written nurse protocol agreement with a delegating physician under O.C.G.A. §43-34-25, implemented through GCMB Chapter 360-32. The protocol is filed with the Board — and, critically, it is read during an investigation.

What the protocol says therefore matters enormously. If it authorizes drug categories that do not include weight-management or anti-obesity agents, it does not authorize GLP-1 prescribing, whatever the practice has been doing for the last two years. This is the single most common structural defect we see in Georgia weight-loss programs, and it is also the easiest to fix: amend the protocol and file it. Our Georgia nurse protocol agreement guide covers the drafting in detail.

The twelve-month refill ceiling most programs miss

Here is a Georgia-specific rule with direct operational bite that almost no national GLP-1 guidance mentions: an APRN prescribing under a nurse protocol agreement cannot authorize refills of any drug for more than twelve months from the date of the original order. The narrow exceptions are oral contraceptives, hormone replacement therapy and prenatal vitamins, which may run to twenty-four months. GLP-1s are not on that list.

Read that against how weight-loss programs are actually run. A patient starts in March, tolerates the drug, settles onto a maintenance dose, and the program quietly reauthorizes month after month. At the twelve-month mark, an APRN-issued order has run out of authority under the protocol — regardless of how well the patient is doing. The protocol must also specify the number of refills that may be ordered, so a protocol silent on refills is not authorizing them at all. Build a hard twelve-month re-order gate into your recall system and have the delegating physician document the decision to continue.

What the May 7, 2026 Position Statement changed

On May 7, 2026 the GCMB issued a Position Statement covering the delegating physician/APRN relationship, the supervising physician/PA relationship, and IV hydration. Its theme is that supervision must be genuine clinical oversight rather than a signature. The Board set out concrete expectations: direct onsite observation at least annually, quarterly medical-record review, and responsibility on the delegating physician for ensuring delegated acts are clinically appropriate and adequately documented. It also expressly targets paid third-party arrangements where a matching service is compensated for access to a delegating physician and routes payment to that physician for the delegation.

For a GLP-1 program the practical translation is that quarterly chart review is now the baseline expectation, and a weight-loss caseload is exactly the kind of high-volume, protocol-driven practice where the absence of review is visible on inspection. A separate 2026 rule change set the supervision ceiling at the combined equivalent of eight APRNs or PAs at any one time.

The Evaluation Georgia Requires Before the First Prescription

Georgia does not publish a checklist for a weight-management evaluation. What it publishes instead is a disciplinary standard: GCMB Rule 360-3-.02 defines unprofessional conduct, and prescribing without an adequate examination falls under it. The chart is the only evidence that the examination happened.

What the evaluation must establish

The evaluation has to be sufficient to support the diagnosis and the treatment plan. For a GLP-1 that means, at minimum:

• Measured anthropometrics — height, weight and BMI recorded by the practice. A self-reported weight typed into a web form is the weakest possible foundation for an obesity diagnosis, and it is trivially attacked.
• Indication — BMI ≥30, or ≥27 with a documented weight-related comorbidity. Name the comorbidity: type 2 diabetes, prediabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease.
• Weight and treatment history — prior attempts, prior anti-obesity medication, bariatric surgery history, current medications and allergies.
• Contraindication screen — the specific screens set out further below, recorded as answered rather than assumed.
• Off-label rationale where a diabetes-labelled product is being used for weight management.
• Informed consent — including gastrointestinal effects, the thyroid C-cell tumour warning, pancreatitis and gallbladder risk, pregnancy considerations, and the expectation of weight regain after discontinuation.
• A written plan — starting dose, titration schedule, follow-up intervals, monitoring, and the criteria that would stop treatment.

Baseline labs

No Georgia statute mandates a lab panel before a GLP-1. Standard of care supplies the answer instead, and the panel a reviewer expects to see is short: HbA1c, a comprehensive metabolic panel covering renal and hepatic function, a lipid panel, TSH where thyroid disease is suspected, and a pregnancy test for patients of childbearing potential. Lipase is worth a baseline where there is any pancreatitis history. Order them, chart the results, and chart what you did about abnormal ones — an unreviewed abnormal result in the file is worse than no result at all.

Telehealth: Can the First GLP-1 Consult Be Virtual in Georgia?

This is the question Georgia operators ask most, and it is the one where the honest answer is uncomfortable: Georgia has not clearly resolved it. Anyone telling you confidently that a video-only first GLP-1 visit is fine in Georgia — or that it is flatly prohibited — is reading one half of the rulebook.

What Rule 360-3-.07 permits

Board Rule 360-3-.07, "Practice Through Electronic or Other Such Means," sets out how a Georgia-licensed physician, PA or APRN may treat by electronic means. It contemplates three routes: the practitioner has personally seen and examined the patient; the practitioner is providing care at the request of another Georgia licensee who has examined the patient; or the practitioner is able to examine the patient using technology and peripherals equal or superior to an examination done personally within that practitioner's standard of care. That third limb is the one telehealth weight-loss programs rely on, and on its face it does permit establishing care remotely.

What cuts the other way

Two things. First, Rule 360-3-.02 defines it as unprofessional conduct to provide treatment by electronic means unless a history and physical examination has been performed by a Georgia licensee. Second, the Board's general position has been that a patient should be examined in person once before an initial prescription is issued for a controlled substance or a dangerous drug. That second word matters: under O.C.G.A. §16-13-71 a "dangerous drug" is any prescription drug that is not a scheduled controlled substance — which is precisely what every GLP-1 is. The rule does carve out prescribing pursuant to a valid physician-patient relationship under O.C.G.A. §33-24-56.4 and prescribing by a licensee who is on call or covering for another.

So Georgia's own instruments point in two directions, and the Board has issued no GLP-1-specific guidance reconciling them. We are not going to paper over that. The defensible operating position — the one that does not depend on winning the argument — is to treat a video-only initial encounter as arguable but not as a program-wide default, and to build an in-person touchpoint into the front of the pathway wherever the patient is reachable. Where the encounter is virtual, use synchronous audio-video with a measured weight, never asynchronous intake alone, and document why the technology met the standard of care for this patient.

The annual in-person expectation

Independent of the first visit, a Georgia telemedicine practitioner is expected to make diligent efforts to ensure the patient is examined in person at least once a year by a Georgia-licensed physician, PA or APRN. For a maintenance-phase weight-loss patient — the population most likely to go years without being physically seen — this is a live obligation. "Diligent efforts" is an evidentiary standard: record the offer, the scheduling attempt, and the patient's response.

What the encounter must produce on paper

Whatever the modality, the encounter should generate: the patient's physical location at the time of service (a Georgia patient means a Georgia-licensed prescriber, unless the prescriber holds a telemedicine licence under O.C.G.A. §43-34-31.1); the prescriber's name, credentials and emergency contact information given to the patient, which Rule 360-3-.07 requires; a separate telehealth consent alongside medical consent; the clinical content of the evaluation above; and a continuity plan naming who handles an emergency and where in-person care will occur.

Administer: Who May Physically Inject a GLP-1 in Georgia

Prescribing and administering are different acts governed by different boards, and a program can have impeccable prescriptive authority while the injection itself is unlawful.

Physicians, PAs and APRNs

All may administer within their scope. For PAs and APRNs the same delegation instrument that authorizes prescribing — the job description or nurse protocol agreement — should also address administration.

Registered nurses

An RN may administer a GLP-1 injection on a valid order from an authorized Georgia prescriber. The RN does not need to be the prescriber and does not need independent authority; the RN needs an order that is patient-specific and issued after the evaluation. What an RN may not do is make the prescribing decision — selecting the patient, choosing the dose, or deciding to escalate — because that is prescribing regardless of the job title on the door.

Licensed practical nurses

An LPN practises under the direction of a physician, dentist, podiatrist or RN, and medication administration by an LPN must sit within that supervised scope and within the LPN's demonstrated competency. Subcutaneous injection of a prescribed drug on a valid order is ordinarily within it. The constraint to watch is supervision: an LPN alone in a treatment room with no physician or RN direction available is a structural problem, not a paperwork one.

Medical assistants and unlicensed staff — a flat no

An unlicensed medical assistant may not inject a GLP-1 in Georgia. The delegation statute, O.C.G.A. §43-34-23, permits a physician to delegate authority to administer drugs to a nurse under a nurse protocol or to a PA under a job description — those are the routes it creates. O.C.G.A. §43-34-22 does not permit a physician to delegate to unlicensed personnel a task that would otherwise require a licence, and administering a prescription drug by injection is such a task.

There is no training certificate, no manufacturer course, no protocol, and no degree of physician presence that converts an unlicensed injector into a lawful one. The same analysis the Board applies to neuromodulator injection applies here, and we set it out in the Georgia injection scope guide. If unlicensed staff are currently injecting in your practice, stop today; it is the highest-severity finding on this page.

Patient self-injection

Most GLP-1 patients inject themselves at home, which is lawful and unremarkable — but the teaching visit is a clinical event and should be charted like one. Record who taught, that the patient performed a return demonstration, the storage and sharps disposal instructions given, missed-dose guidance, and the symptoms that should prompt a call.

Compound: 503A, 503B, and What a Georgia Med Spa May Still Source

Sourcing is where the last three years of med spa weight-loss economics collapsed, and where the largest number of Georgia programs are still operating on assumptions that expired in 2025.

What the shortage delistings changed

Section 503A of the Food, Drug, and Cosmetic Act bars a compounding pharmacy from compounding a drug that is essentially a copy of a commercially available FDA-approved product. A drug shortage suspends that bar. Both GLP-1 shortages have ended: the FDA removed tirzepatide from its shortage list in October 2024 and semaglutide on February 21, 2025. The transition periods followed — 503A pharmacies had until February 19, 2025 for tirzepatide and April 22, 2025 for semaglutide; 503B outsourcing facilities had until March 19 and May 22, 2025 respectively. All four dates are long past.

The April 30, 2026 FDA proposal

On April 30, 2026 the FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B Bulks List — the list of substances outsourcing facilities may compound from bulk — on the basis that there is no clinical need for them absent a shortage. Note the status carefully: as of this update it is a proposal, not a final rule. If finalized it would close the remaining large-scale compounding route for these molecules. Any Georgia program still depending on a 503B supply should be planning for that outcome now rather than treating the proposal as distant.

What remains lawful, narrowly

Compounding has not vanished. What survives is patient-specific and documented: a formulation that is genuinely not essentially a copy — a dose or form clinically necessary for this patient and unavailable in the approved product — or a documented intolerance to an inactive ingredient. The word doing the work is documented, in this patient's chart, before the order. Cost is not a clinical difference. Patient preference is not a clinical difference. "We have always used compounded" is not a clinical difference. The full mechanics, including salt-form issues and supplier vetting, are in our 503A vs 503B compounded GLP-1 guide — this section is the Georgia-facing summary of it.

The "research peptide" trap

As branded supply normalized and compounding closed, a grey market moved in: peptides sold as "research use only" or "not for human consumption," often semaglutide, tirzepatide or retatrutide analogues, shipped with bacteriostatic water and no pharmacy in the chain at all. The FDA has been issuing warning letters against exactly this, including to Gram Peptides and Mile High Compounds on March 31, 2026, on the basis that products advertised for human use are unapproved new drugs regardless of the disclaimer on the label.

For a Georgia med spa this is not a grey area, it is the worst available position: no lawful prescription behind the product, no permitted pharmacy in the chain, no sterility assurance, and nothing for a malpractice carrier or a medical director to stand on. If a supplier's site carries a research-use disclaimer, that disclaimer is the tell.

The Georgia Pharmacy Side: Board of Pharmacy, GDNA, and Your Supplier

Georgia splits pharmacy oversight in a way that surprises operators from other states. The Georgia State Board of Pharmacy issues the permits; the Georgia Drugs and Narcotics Agency conducts the inspections and investigations and refers matters back to the Board. When something goes wrong with your supply chain, GDNA is the agency you will meet.

Non-resident pharmacies must hold a Georgia permit

An out-of-state pharmacy may ship, mail or deliver dispensed drugs into Georgia only if it holds a non-resident pharmacy permit from the Georgia Board of Pharmacy under O.C.G.A. §26-4-114.1. The applicant must show a valid pharmacy licence in its home state, identify its principal corporate officers and the pharmacist in charge of dispensing to Georgia residents, and affirm compliance with the regulators of every state where it is licensed. The Board may ask the home-state regulator to inspect, at the pharmacy's expense.

This is the single most useful verification a Georgia med spa can perform, and it takes ten minutes.

What to demand in writing from any supplier

Before the first order, and annually thereafter, put the following in your supplier file:

• The Georgia pharmacy permit or non-resident pharmacy permit number, plus the home-state licence, both verified as active rather than merely asserted.
• Registration status: 503A pharmacy, 503B outsourcing facility, or wholesale distributor — stated explicitly, because the obligations differ.
• For any compounded preparation, the specific patient-specific clinical basis relied on, matched to a chart entry you wrote.
• Product source documentation for branded product: NDC, lot, expiry, and confirmation it was acquired through the legitimate distribution chain.
• The pharmacist-in-charge's name and a direct contact for adverse events and recalls.
• Written confirmation that the pharmacy does not supply, and will not substitute, research-grade or non-pharmacy-sourced material.

A supplier that hesitates at any of these has answered the question. Keep the file where you could hand it to a GDNA inspector without preparation, because that is the circumstance in which it will be requested.

Contraindications and the Screens Georgia Charts Most Often Lack

Contraindication screening is clinically obvious and evidentially fragile: everyone does some version of it, and very few charts prove it. In a Board review, an unrecorded screen is an unperformed screen.

The absolute ones

GLP-1 receptor agonist labelling carries a boxed warning regarding thyroid C-cell tumours. Treatment is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2. Note that the family-history limb is what makes this a screening question rather than a records question — you cannot find it in the patient's own history, so you have to ask, and you have to record the answer.

Also contraindicated or requiring a documented risk decision: prior serious hypersensitivity to the agent; pregnancy, and pregnancy planning, given the recommendation to discontinue well in advance of a planned conception; and breastfeeding.

The cautions that need a documented decision

• Pancreatitis history — a relative contraindication requiring an explicit risk-benefit note, not silence.
• Gastroparesis and significant gastrointestinal disease — GLP-1s slow gastric emptying by design.
• Gallbladder disease — rapid weight loss raises cholelithiasis risk.
• Diabetic retinopathy — rapid glycaemic improvement can worsen it; document the ophthalmology plan.
• Concurrent insulin or sulfonylureas — hypoglycaemia risk requiring dose adjustment and coordination with the prescribing clinician.
• Renal impairment — dehydration from vomiting and diarrhoea can precipitate acute kidney injury.
• Eating disorder history and psychiatric status — screen and record; this is the omission most likely to become the centrepiece of a complaint.

Peri-procedural and anaesthesia disclosure

Delayed gastric emptying has produced anaesthesia guidance about aspiration risk in patients on GLP-1s. Your consent and patient instructions should tell the patient to disclose GLP-1 use before any procedure requiring sedation or anaesthesia. It costs one paragraph and closes a real risk.

Monitor: Titration, Follow-Up, Off-Ramping, and Adverse Events

Georgia sets no statutory follow-up interval for weight-management prescribing. Standard of care sets it, and the GCMB's May 2026 emphasis on quarterly record review by the delegating physician gives an APRN-run program a concrete rhythm to meet.

A defensible visit cadence

• 4 weeks after initiation — tolerance, adverse effects, adherence, injection technique, weight response, titration decision.
• Every 4–12 weeks during titration — one encounter per dose escalation, documented as a decision rather than a refill.
• At least every 3 months on maintenance — which also aligns with the Board's quarterly chart-review expectation.
• Annually — repeat HbA1c, renal and hepatic function and lipids, and address the in-person examination expectation.
• At 12 months — for APRN-issued orders, the hard refill ceiling discussed above forces a documented continuation decision.

What each follow-up note must contain

A titration note that says "tolerating well, increase dose" is not a defensible note. Each entry should carry the current dose and the dose being moved to, measured weight and the percentage change from baseline, adverse effects and what was done about them, adherence and missed doses, blood pressure and glycaemic data where relevant, any concomitant medication changes, and the clinical reasoning for escalating, holding or stopping. Reasoning is what distinguishes a chart from a shipping log.

Stop criteria, written before you start

Define discontinuation criteria in the SOP so the decision is not improvised: less than 5% weight loss after 12 weeks at the maintenance dose; intolerable adverse effects that do not resolve with dose reduction; suspected pancreatitis; pregnancy or pregnancy intent; a new contraindication; or a patient lost to follow-up, which should stop the prescription rather than trigger an automatic refill.

Off-ramping and maintenance

Weight regain after discontinuation is expected, well documented, and needs to be in the consent conversation at the start rather than the exit conversation at the end. Whether the plan is indefinite maintenance, a dose-reduction taper, or a structured stop with nutrition and resistance-training support, it should be written, discussed and charted — including muscle mass preservation and protein intake, which is where most maintenance plans are thin. Our GLP-1 maintenance and off-ramping guide covers the protocol design, and the GLP-1 monitoring schedule template gives you the visit-by-visit structure to drop into an EMR.

Adverse events: recognition and management

Staff should be able to distinguish routine gastrointestinal effects from the events that need urgent evaluation: severe persistent abdominal pain radiating to the back, with or without vomiting, suggesting pancreatitis; right upper quadrant pain, fever or jaundice suggesting gallbladder disease; symptomatic hypoglycaemia in patients on insulin or a sulfonylurea; dehydration and acute kidney injury from protracted vomiting or diarrhoea; and hypersensitivity reactions. Every practice should hold a written protocol saying who is called, what is documented, and when the patient is sent to emergency care rather than rescheduled.

Reporting

Serious adverse events should be reported to the FDA through MedWatch and to the manufacturer. If a compounded product is involved, report it and preserve the vial, the label, the lot number and the pharmacy paperwork. Maintain an internal adverse-event log — the GCMB's interest in a complaint is rarely limited to the index patient, and a log is what lets you answer the question about everyone else.

Overprescribing and the Georgia Composite Medical Board

One clarification first, because this page previously overstated it and other sources still do: the GCMB has not published GLP-1-specific enforcement guidance or a weight-loss prescribing rule. What exists is the general disciplinary framework in O.C.G.A. Title 43, Chapter 34 and Rule 360-3-.02, applied to weight-loss practice the same way it is applied to anything else. The patterns below are what that framework makes actionable — not a tally of published Georgia GLP-1 cases.

Pattern 1 — the intake form as the entire encounter

A web questionnaire, a clinician the patient never speaks to, and a prescription. This is the pattern that maps most directly onto Rule 360-3-.02's electronic-treatment provision, and it is aggravated rather than cured by volume: the more patients behind it, the clearer the inference that no individual assessment occurred.

Pattern 2 — a protocol that does not cover the drug

An APRN prescribing GLP-1s under a nurse protocol agreement that never mentions weight-management agents. The Board has the filed document and will read it against the prescriptions. This is a documentary defect, which means it cannot be argued away with clinical outcomes.

Pattern 3 — the absent delegating physician

A signature on a protocol, no chart review, no onsite presence, no reachable availability. After the May 7, 2026 Position Statement this is squarely in the Board's sights, and the expectations — annual onsite observation, quarterly record review — are now specific enough that their absence is easy to demonstrate.

Pattern 4 — refills without encounters

Twelve or eighteen months of continuous supply with no documented follow-up. In an APRN-run program this compounds: it is both a standard-of-care problem and, past twelve months, a refill-authority problem under the nurse protocol rules.

Pattern 5 — screening gaps in the chart

No recorded MTC or MEN-2 family history, no pregnancy screen, no pancreatitis question. A boxed warning that the chart does not engage with is the easiest finding a reviewer can make.

Pattern 6 — advertising that contradicts the clinical workflow

Marketing promising GLP-1s with no doctor visit, or same-day approval for everyone, invites the Board to compare the promise against the charts. When the advertising describes a faster process than the records can support, the advertising becomes the evidence.

Advertising a Georgia GLP-1 Program

Georgia regulates practitioner advertising more specifically than most states, and 2026 has been an active federal enforcement year on precisely this subject.

The Georgia requirements

O.C.G.A. §43-1-33 requires a health care practitioner's advertisement to include the practitioner's name and to disclose the type of licence under which services are provided, and prohibits deceptive or misleading terms and false representations. In practice that means a GLP-1 landing page should make clear who is treating and what licence they hold — the common failure is a page that markets a clinical service while naming no clinician at all. Separately, O.C.G.A. §43-34-8 makes untruthful or improbable statements, flamboyant or extravagant claims about professional excellence, and misleading or deceptive representations grounds for discipline.

Where the FDA and FTC bite

Federal enforcement has focused on compounded GLP-1 marketing. The FDA issued 30 warning letters to telehealth firms earlier in 2026 over false or misleading claims, and published a further round to 25 companies on June 16, 2026, covering claims issued on June 8. The recurring violation is presenting a compounded product as though it were FDA-approved or clinically equivalent to Wegovy, Ozempic, Zepbound or Mounjaro. On the FTC side, a final order against telehealth provider NextMed over deceptive GLP-1 weight-loss advertising was approved in December 2025.

Claims to remove today

• Any guaranteed or specific promised weight loss — "lose 20 pounds in 8 weeks."
• Any suggestion that a compounded product is FDA-approved, or "the same as" a branded product.
• "No doctor visit needed," "instant approval," or anything implying the evaluation is a formality.
• Before-and-after imagery without disclosure that results are not typical, and without consent on file for the images.
• Use of brand names — Ozempic, Wegovy, Zepbound, Mounjaro — to advertise a product you are not actually dispensing.
• Testimonials describing outcomes your own charts would not support.

Ownership and the Delegating-Physician Relationship

Georgia is comparatively permissive on med spa ownership — non-physician ownership is not per se prohibited the way it is in strict corporate-practice states, which is a large part of why Georgia has attracted so many APP-owned weight-loss practices. That permissiveness is exactly what the GCMB's May 2026 Position Statement responds to.

The Board's concern is not who owns the entity; it is whether clinical authority is real. The Position Statement requires supervisory relationships to reflect genuine clinical oversight and cannot be structured to circumvent statutory supervision requirements — and it expressly addresses paid third-party matching services where a company is compensated for access to or assignment of a delegating physician and that physician is compensated through the arrangement. Ordinary physician employment, locum arrangements and direct contracting are not what is targeted; intermediaries profiting from the supervisory relationship itself are.

For a weight-loss program specifically, treat the delegating physician relationship as an operating input rather than an annual formality. That means a named physician who has read the GLP-1 SOP and signed it, quarterly documented chart review, annual onsite observation, reachable availability during operating hours, involvement when the protocol changes, and a compensation arrangement that does not run through a matching platform. Our Georgia medical director requirements guide covers the agreement structure and what the Board expects to see in it.

Records, Consent, and Retention

Retention in Georgia is longer than most operators assume and starts earlier. Under O.C.G.A. §31-33-2, a provider with custody of an evaluation, diagnosis, prognosis, laboratory report or biopsy slide must retain that item for at least ten years from the date the item was created. The clock runs per item, from creation — not from the last visit, not from program discharge. For a weight-loss patient treated over three years, the initial evaluation ages out three years before the final titration note does, so retention has to be managed at the document level.

The consent set for a Georgia GLP-1 program should include: medical informed consent covering the boxed thyroid C-cell warning, gastrointestinal effects, pancreatitis and gallbladder risk, pregnancy considerations and expected weight regain after discontinuation; a specific off-label consent where a diabetes-labelled product is used for weight management; a separate telehealth consent where any encounter is virtual; consent for photographs if images are taken; financial consent, particularly for membership or auto-renewing programs; and a HIPAA notice with authorization for any release.

Two operational points. First, if your program auto-charges, the financial consent and the clinical continuation decision must be separable — a payment that renews automatically while the prescription requires a clinical decision is fine; a prescription that renews because a payment did is not. Second, keep the delegation instruments with the clinical records: the nurse protocol agreement, the PA job description, the medical director agreement and the supplier permits are the documents most likely to be requested first and found slowest.

The Build-It Checklist: What You Must Produce on Demand

If a GDNA inspector or a GCMB investigator arrived tomorrow, a compliant Georgia GLP-1 program should be able to produce all of the following without preparation:

1. A written GLP-1 SOP signed and dated by the medical director, covering eligibility, contraindications, titration, monitoring, adverse events and discontinuation.
2. The nurse protocol agreement, filed with the Board, explicitly covering weight-management agents and specifying the number of refills authorized.
3. The PA job description as approved by the GCMB, with prescriptive authority stated.
4. The medical director or delegating physician agreement, with the compensation arrangement and no third-party matching intermediary.
5. Chart-review records evidencing quarterly review, and a log of annual onsite observation.
6. The patient evaluation template capturing measured BMI, indication, comorbidities, history and screens.
7. The contraindication screening form, including the MTC/MEN-2 family history question and pregnancy screen.
8. Informed consent forms — medical, off-label, telehealth, photography, financial.
9. Baseline and follow-up lab records with documented review of abnormal results.
10. Titration and follow-up notes showing clinical reasoning at each dose change.
11. The supplier file — Georgia pharmacy or non-resident permit numbers verified active, registration type, and product source documentation.
12. Compounding justification in the chart for any compounded preparation dispensed.
13. The adverse event log and the written emergency response protocol.
14. Recall and follow-up workflow evidence, including the twelve-month re-order gate for APRN-issued orders.
15. Staff licence verifications for everyone who administers injections, with scope documented.
16. Advertising review records showing current claims were checked against O.C.G.A. §43-1-33 and §43-34-8.

Most Georgia programs we review can produce eight or nine of the sixteen. The gaps cluster in the same three places every time: the protocol that does not name the drug category, the chart review that was never documented, and the supplier file that was never built. For the broader Georgia picture across every service line, work through the Georgia med spa compliance checklist, and browse the rest of our state coverage on the Georgia resource hub. If you are still deciding how to structure the practice itself, the templates and kits on our homepage are organized by service line.

Disclaimer: This article is for educational purposes only and does not constitute legal or medical advice. GLP-1 prescribing involves federal and state regulatory considerations that change frequently. Verify current FDA shortage status and consult with a Georgia healthcare attorney and your medical director before establishing or modifying a weight-loss program.